

DAFTAR PUSTAKA

- Abraham, H.M., White, M., dan White, W.B., 2015. The Comparative Efficacy and Safety of the Angiotensin Receptor Blockers in the Management of Hypertension and Other Cardiovascular Diseases. *Drug Safety*, **38**: 33–54.
- Agarwal, R., Pogue, V., Rahman, M., Reisin, E., dan Weir, M.R., 2014. Assessment and Management of Hypertension in Patients on Dialysis. *American Society of Nephrology*, **25**: 1630–1646.
- Ahmadmehrabi, S. dan Tang, W.H.W., 2018. Hemodialysis-induced Cardiovascular Disease. *Seminars in Dialysis*, **31**: .
- Andayani, T.M., 2013. *FARMAKOEKONOMI: Prinsip Dan Metodologi*. Bursa Ilmu, Yogyakarta.
- Balitbangkes, 2013. 'Riset Kesehatan Dasar 2013', . Kemenkes RI.
- Benetos, A., Petrovic, M., dan Strandberg, T., 2019. Hypertension Management in Older and Frail Older Patients. *Circulation Research*, **124**: 1045–1060.
- Benowitz, N.L., 2012. Section II Cardiovascular renal Drugs, dalam: Katzung, B.G. (Editor), *Basic and Clinical Pharmacology*. McGraw-Hill, New York, hal. 169–190.
- Birkett, M.A. dan Day, S.J., 1994. Internal pilot studies for estimating sample size. *Statistics in Medicine*, **13**: 2455–2463.
- Bloomfield, D. dan Park, A., 2015. Night Time Blood Pressure Dip. *World Journal of Cardiology*, **7**: .
- Conlin, P.R., Spence, J.David., Williams, B., dan Ribeiro, A.B., 2000. Angiotensin II Antagonists for Hypertension: Are There Differences in Efficacy? *American Journal of Hypertension*, **13**: .
- Dandan, R.H., 2018. Renin and Angiotensin, dalam: *Goodman&Gilman's The Pharmacological Basis of Therapeutics*. McGraw-Hill Education, New York.
- Drawz, P.E., Alper, A.B., dan Anderson, A.H., 2016. Masked Hypertension and Elevated Nighttime Blood Pressure in CKD: Prevalence and Association with Target Organ Damage. *American Society of Nephrology*, **11**: 642–652.

- Eckardt, K.-U., Gillespie, I.A., Kronenberg, F., Richards, S., Stenvinkel, P., Anker, S.D., dkk., 2015. High cardiovascular event rates occur within the first weeks of starting hemodialysis. *Kidney International*, **88**: 1117–1125.
- Fliser, D., Franek, E., Joest, M., dan Block, S., 1997. Renal function in the elderly: impact of hypertension and cardiac function. *Kidney International*, **51**: 1196–1204.
- Fu, E.L., Clase, C.M., Evans, M., Lindholm, B., Rotmans, J.I., Dekker, F.W., dkk., 2021. Comparative Effectiveness of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in Individuals With Advanced CKD: A Nationwide Observational Cohort Study. *American Journal of Kidney Diseases*, **77**: 719-729.e1.
- Gaba, P., Pedrotty, D., dan DeSimone, C.V., 2020. Mortality in Patients With Right Bundle-Branch Block in the Absence of Cardiovascular Disease. *Journal of the American Heart Association*, **9**: .
- Haider, D.G., Sauter, T., dan Lindner, G., 2015. Use of Calcium Channel Blockers is Associated with Mortality in Patients with Chronic Kidney Disease. *Kidney and Blood Pressure Research*, **40**: 630–637.
- Hemmelgarn, B.R., Manns, B.J., Quan, H., dan Ghali, W.A., 2003. Adapting the charlson comorbidity index for use in patients with ESRD. *American Journal of Kidney Diseases*, **42**: 125–132.
- James, P.A., Oparil, S., Carter, B.L., Cushman, W., dan Dennison-Himmelfarb, C., 2013. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). *American Medical Association*, .
- Jankowski, J., Floege, J., Fliser, D., Böhm, M., dan Marx, N., 2021. Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options. *Circulation*, **143**: 1157–1172.
- Jeong, H.S., Lim, H., Park, H.-J., Lee, W.-S., Choi, J.-O., Lee, H.S., dkk., 2021. Clinical outcomes between calcium channel blockers and angiotensin receptor blockers in hypertensive patients without established cardiovascular diseases during a 3-year follow-up. *Scientific Reports*, **11**: 1783.
- KDIGO CKD Work Group, 2013. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney International Supplements*, **III**: 1–150.
- Kemenkes RI, 2017. 'Infodatin: Situasi Penyakit Ginjal Kronis' . *Infodatin*, 8–10.

- Kemenkes RI, 2018. 'Hasil Utama Riskesdas 2018'. Kementrian Kesehatan Badan Penelitian dan Pengembangan Kesehatan.
- Kemenkes RI, K.R., 2013. *Pedoman Penerapan Kajian Farmakoeкономи. Direktorat Jenderal Bina Kefarmasian dan Alat Kesehatan*, Jakarta.
- Kim-Mitsuyama, S., Ogawa, H., Matsui, K., Jinnouchi, T., Jinnouchi, H., Arakawa, K., dkk., 2013. An angiotensin II receptor blocker–calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone. *Kidney International*, **83**: 167–176.
- Koulouridis, I., Alfayez, M., Trikalinos, T.A., dan Balk, E.M., 2013. Dose of Erythropoiesis-Stimulating Agents and Adverse Outcomes in CKD: A Metaregression Analysis. *AJKD*, **61**: 44–56.
- Lemeshow, S., Hosmer Jr., D.W., Klar, J., dan Lwanga, S.K., 1997. *Besar Sampel Dalam Penelitian Kesehatan*. Gadjah Mada University Press.
- Lewis, E.J., Hunsicker, L.G., dan Clarke, W.R., 2001. RENOPROTECTIVE EFFECT OF THE ANGIOTENSIN-RECEPTOR ANTAGONIST IRBESARTAN IN PATIENTS WITH NEPHROPATHY DUE TO TYPE 2 DIABETES. *The New England Journal of Medicine*, **345**: 852–860.
- Lin, Y.-C., Lin, J.-W., Wu, M.-S., Chen, K.-C., Peng, C.-C., dan Kang, Y.-N., 2017. Effects of calcium channel blockers comparing to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with hypertension and chronic kidney disease stage 3 to 5 and dialysis: A systematic review and meta-analysis. *PLOS ONE*, **12**: e0188975.
- Lutz, J., Menke, J., dan Sollinger, D., 2014. Haemostasis in chronic kidney disease. *Nephrology Dialysis Transplantation*, **29**: 29–40.
- Michel, B., Lin, S., Ruilope, L., Bader, G., Durg, S., dan Brunel, P., 2019. Effect of angiotensin receptor blockers on blood pressure and renal function in patients with concomitant hypertension and chronic kidney disease: a systematic review and meta-analysis. *Blood Pressure*, .
- Mitrovic, I., 2019. Cardiovascular Disease: Vascular Disease, dalam: Hammer, G.D. dan McPhee, S.J. (Editor), *Pathophysiology of Disease: An Introduction to Clinical Medicine*. McGraw-Hill Education, New York, hal. 778–788.
- Munger, M.A., 2011. Drug Class Review: Use of Angiotensin Receptor Blockers In Cardiovascular Protection. *Pharmacy and Therapeutics*, **36**: 22–40.

- Munoz-Durango, N., Fuentes, C.A., Castillo, A.E., dan Gonzales-Gomez, L.M., 2016. Role of the Renin-Angiotensin-Aldosterone System beyond Blood Pressure Regulation: Molecular and Cellular Mechanisms Involved in End-Organ Damage during Arterial Hypertension. *International Journal of Molecular Science*, **17**: .
- Park, C., Wang, G., Durthaler, J.M., dan Fang, J., 2017. Cost-effectiveness Analyses of Antihypertensive Medicines: A Systematic Review. *American Journal of Preventive Medicine*, **53**: S131–S142.
- Pattanaprteep, O., Ingsahit, A., McEvoy, M., Attia, J., dan Thakkestian, A., 2018. Cost-Effectiveness Analysis of Renin-Angiotensin Aldosterone System Blockade in Progression of Chronic Kidney Disease. *International Society for Pharmacoeconomics and Outcomes Research*, .
- Perlman, R.L. dan Heung, M., 2019. Renal Disease, dalam: Hammer, G.D. dan McPhee, S.J. (Editor), *Pathophysiology of Disease: An Introduction to Clinical Medicine*. McGraw-Hill Education, New York, hal. 1127–1133.
- Pinzon, R.T., Padmanaba, M.B.H., Pramudita, E.A., dan Sugianto, 2019. Pola Terapi pada Faktor Risiko Kardioserebrovaskuler Pasien Penyakit Ginjal Kronis yang Menjalani Hemodialisis. *Jurnal Farmasi dan Ilmu Kefarmasian Indonesia*, **6**: 32–36.
- Prasetyo, E.Y., Oetari, dan Wijayanti, T., 2015. Evaluasi Penggunaan Obat Antihipertensi pada Penyakit Hipertensi Disertai Gagal Ginjal Kronik (ICD I12.0) Pasien Geriatri Rawat Inap di RSUD A.W. Sjahrani Samarinda pada Tahun 2012 dan 2013 dengan Metode ATC/DDD. *Jurnal Farmasi Indonesia*, **12**: 23–32.
- Pugh, D., Gallacher, P.J., dan Dhaun, N., 2019. Management of Hypertension in Chronic Kidney Disease. *Drugs*, **79**: 365–379.
- Ruiz de Castroviejo, E.V., Peralez, C.S., dan Lopez, J.L., 2008. Prevalence and Predisposing Factors for Bundle Branch Block in Patients Starting Dialysis. *Rev Esp Cardiol*, **61**: 719–725.
- Saju, A.P., Edakkarayil, A.C., Maheswai, E., dan Gurudev KC, 2016. PRESCRIBING PATTERN AND COST EFFECTIVENESS ANALYSIS OF ANTIHYPERTENSIVE DRUGS IN CHRONIC KIDNEY DISEASE PATIENTS. *European Journal of Pharmaceutical and Medical Research*, **7**.
- Saleem TS., M., Karthik, K., Sreeja, N., dan Sree, B., 2019. Cost effectiveness analysis of anti-hypertensive drug use for chornic kidney disease patient. *International Journal of Research in Pharmaceutical Sciences*, **10**: .

- Sarafidis, P.A., Li, S., Chen, S.-C., dan Collins, A.J., 2008. Hypertension Awareness, Treatment, and Control in Chronic Kidney Disease. *The American Journal of Medicine*, **121**: 332–340.
- Sarnak, M.J., Amann, K., Bangalore, S., Cavalcante, J.L., Charytan, D.M., Craig, J.C., dkk., 2019. Chronic Kidney Disease and Coronary Artery Disease. *Journal of the American College of Cardiology*, **74**: 1823–1838.
- Saseen, J.J. dan MacLaughlin, E.J., 2017. Chapter 13: Hypertension, dalam: Dipiro, J.T. (Editor), *Pharmacotherapy: A Pathophysiologic Approach*. McGraw-Hill Education, New York, hal. 496–556.
- Shroff, G.R., Li, S., dan Herzog, C.A., 2017. Trends in Discharge Claims for Acute Myocardial Infarction among Patients on Dialysis. *American Society of Nephrology*, **28**: .
- Sinha, A.D. dan Agarwal, R., 2019. Clinical Pharmacology of Antihypertensive Therapy for the Treatment of Hypertension in CKD. *Clinical Journal of the American Society of Nephrology*, **14**: 757–764.
- Suzuki, H., Kanno, Y., Sugahara, S., Ikeda, N., Shoda, J., Takenaka, T., dkk., 2008. Effect of Angiotensin Receptor Blockers on Cardiovascular Events in Patients Undergoing Hemodialysis: An Open-Label Randomized Controlled Trial. *American Journal of Kidney Diseases*, **52**: 501–506.
- Szczzech, L.A., Barnhart, H.X., Inrig, J.K., dan Reddan, D.N., 2008. Secondary analysis of the CHOIR trial epoetin-a dose and achieved hemoglobin outcomes. *International Society of Nephrology*, **74**: 791–798.
- Takahashi, A., Takase, H., Toriyama, T., Sugiura, T., Kurita, Y., Ueda, R., dkk., 2006. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis—a randomized study. *Nephrology Dialysis Transplantation*, **21**: 2507–2512.
- Tomey, M.I. dan Winston, J.A., 2014. Cardiovascular Pathophysiology in Chronic Kidney Disease: Opportunities to Transition from Disease to Health. *Annals of Global Health*, **80**: 69.
- Trevor, A.J., Katzung, B.G., dan Kruideng-Hall, M., 2015. *Katzung&Trevor's Pharmacology Examination&Board Review*, 11th ed. McGraw-Hill Education, New York.
- Tsoi, B., Akioyamen, L.E., Bonner, A., Frankfurter, C., dan Levine, M., 2018. Comparative Efficacy of Angiotensin II Antagonists in Essential Hypertension: Systematic Review and Network Meta-Analysis of Randomised Controlled Trials. *Heart, Lung and Circulation*, **27**: .

- Unger, T., Borghi, C., Charchar, F., dan Khan, N.A., 2020. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. *AHA Journal*, 1334–1355.
- Wanner, C., Amann, K., dan Shoji, T., 2016. The heart and vascular system in dialysis. *Lancet*, .
- Widhayanti, C. dan Prasetyo, S.D., 2014. EVALUASI PENGGUNAAN OBAT ANTIHIPERTENSI PADA PASIEN GAGAL GINJAL KRONIK DI INSTALASI RAWAT INAP RS BETHESDA YOGYAKARTA.
- Wiguna, G.N.C., Ahmad, R.A., dan Utarini, A., 2013. Biaya Pelayanan Hemodialisis Peserta Asuransi Kesehatan Menurut Perspektif Pasien di Rumah Sakit Umum Daerah Tipe B, Provinsi Bali. *Jurnal Manajemen Pelayanan Kesehatan*, **16**: 37–45.
- Williams, B., Mancia, G., dan Spiering, W., 2018. 2018 ESC/ESH Guidelines for the management of arterial hypertension | European Heart Journal | Oxford Academic. *European Heart Journal*, **39**: 3021–3104.
- Wright, J. dan Hutchison, A., 2009. Cardiovascular disease in patients with chronic kidney disease. *Vascular Health and Risk Management*, **5**: 10.
- Xie, X., Liu, Y., Perkovic, V., Li, X., Ninomiya, T., Hou, W., dkk., 2016. Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials. *American Journal of Kidney Diseases*, **67**: 728–741.
- Yamamoto, S. dan Kon, V., 2009. Mechanisms for increased cardiovascular disease in chronic kidney dysfunction: *Current Opinion in Nephrology and Hypertension*, **18**: 181–188.
- Zhao, H.-J., Li, Y., Liu, S.-M., Sun, X.-G., Li, M., Hao, Y., dkk., 2016. Effect of calcium channels blockers and inhibitors of the renin-angiotensin system on renal outcomes and mortality in patients suffering from chronic kidney disease: systematic review and meta-analysis. *Renal Failure*, **38**: 849–856.